Product Sales

3 Months Ended

Mar. 31, 2022

Revenue from Contract with Customer [Abstract]

Product Sales

Product Sales

Net product sales consist of the following:

(In millions)	Three Months Ended March 31,
Net Product Sales in the United States	2022			2021
EYLEA®	$	1,517.6		$	1,347.0
Libtayo®	78.9			69.1
Praluent®	33.6			43.3
REGEN-COV®*	—			262.2
Evkeeza®	8.5			0.5
ARCALYST®	—		**	2.2
	$	1,638.6		$	1,724.3
* Net product sales of REGEN-COV in the United States relate to product sold in connection with our agreements with the U.S. government. See Note 3 for further details.
** Effective April 1, 2021, Kiniksa records net product sales of ARCALYST in the United States. Previously, the Company recorded net product sales of ARCALYST in the United States.

As of March 31, 2022 and December 31, 2021, the Company had $3.664 billion and $5.059 billion, respectively, of trade accounts receivable that were recorded within Accounts receivable, net.

The Company had product sales to certain customers that accounted for more than 10% of total gross product revenue for the three months ended March 31, 2022 and 2021. Sales to each of these customers as a percentage of the Company's total gross product revenue are as follows:

	Three Months Ended March 31,
	2022		2021
Besse Medical, a subsidiary of AmerisourceBergen Corporation	55	%	46	%
McKesson Corporation	30	%	29	%
U.S. government	—	%	13	%